SurModics/$SRDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About SurModics
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Ticker
$SRDX
Sector
Primary listing
Employees
389
Headquarters
Website
SurModics Metrics
BasicAdvanced
$390M
-
-$1.24
1.31
-
Price and volume
Market cap
$390M
Beta
1.31
52-week high
$40.21
52-week low
$26.00
Average daily volume
118K
Financial strength
Current ratio
3.909
Quick ratio
2.877
Long term debt to equity
26.652
Total debt to equity
26.652
Interest coverage (TTM)
-0.40%
Profitability
EBITDA (TTM)
7.054
Gross margin (TTM)
76.22%
Net profit margin (TTM)
-14.59%
Operating margin (TTM)
-1.17%
Effective tax rate (TTM)
-19.98%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-0.52%
Return on equity (TTM)
-15.36%
Valuation
Price to revenue (TTM)
3.214
Price to book
3.5
Price to tangible book (TTM)
8.99
Price to free cash flow (TTM)
-109.505
Free cash flow yield (TTM)
-0.91%
Free cash flow per share (TTM)
-0.249
Growth
Revenue change (TTM)
-0.02%
Earnings per share change (TTM)
1,151.84%
3-year revenue growth (CAGR)
7.25%
10-year revenue growth (CAGR)
7.27%
3-year earnings per share growth (CAGR)
10.31%
10-year earnings per share growth (CAGR)
2.59%
What the Analysts think about SurModics
Analyst ratings (Buy, Hold, Sell) for SurModics stock.
Bulls say / Bears say
Excluding SurVeil DCB license fee revenue, Q3 FY2025 revenue rose 1% year-over-year to $29.6 million, reversing the declines observed earlier in the year (Business Wire).
Adjusted EBITDA increased to $3.4 million in Q3 FY2025 from $1.6 million a year earlier, demonstrating improved operating leverage and better cost management (Business Wire).
Surmodics launched the Pounce XL Thrombectomy System commercially in April 2025, expanding its vascular intervention product lineup and potentially driving future growth for the Medical Device segment (Business Wire).
Total revenue declined 12% year-over-year to $28.1 million in Q2 FY2025, with revenue excluding SurVeil DCB license fees falling 10%, which indicates weak demand in key segments (Business Wire).
Surmodics posted GAAP net losses of $5.2 million in Q2 and $5.3 million in Q3 FY2025, highlighting ongoing unprofitability as the company has not achieved a profitable quarter over the last two fiscal quarters (Business Wire, Business Wire).
The U.S. FTC filed a lawsuit in March 2025 to block the planned $627 million GTCR acquisition, introducing significant legal uncertainty and the risk that the deal collapses, which could negatively impact shareholder value (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
SurModics Financial Performance
Revenues and expenses
SurModics Earnings Performance
Company profitability
SurModics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SurModics stock?
SurModics (SRDX) has a market cap of $390M as of October 28, 2025.
What is the P/E ratio for SurModics stock?
The price to earnings (P/E) ratio for SurModics (SRDX) stock is 0 as of October 28, 2025.
Does SurModics stock pay dividends?
No, SurModics (SRDX) stock does not pay dividends to its shareholders as of October 28, 2025.
When is the next SurModics dividend payment date?
SurModics (SRDX) stock does not pay dividends to its shareholders.
What is the beta indicator for SurModics?
SurModics (SRDX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.